Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 13/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6279720 | 0.80 | NR1H3 (0.50) | MLYCDNR1H3NR1H2ALDH1A1HPGD | |
| SCHEMBL19601 | 0.77 | ALDH1A1 (0.54) | ALDH1A1HPGDSMN1; SMN2HDAC4 | |
| SCHEMBL27824460 | 0.74 | ALDH1A1 (0.36) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL27582338 | 0.72 | ALDH1A1 (0.35) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL11409191 | 0.72 | MLYCD (0.43) | MLYCDNR1H3NR1H2ALDH1A1HPGD | |
| SCHEMBL6969493 | 0.71 | ALDH1A1 (0.35) | MLYCDALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL1642738 | 0.71 | MLYCD (0.51) | MLYCDALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2902770 | 0.71 | HDAC4 (0.42) | MLYCDALDH1A1HPGDSMN1; SMN2HDAC4 | |
| SCHEMBL608510 | 0.69 | CES1 (0.60) | MLYCD | |
| SCHEMBL467330 | 0.68 | HPGD (0.56) | MLYCDALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TIE1, KDR, FLT1 | MLYCD 4643/4885NR1H3 4386/4885NR1H2 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.